

Monique E Hinchcliff

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6536315/publications.pdf>

Version: 2024-02-01

80
papers

5,364
citations

94433

37
h-index

88630

70
g-index

84
all docs

84
docs citations

84
times ranked

7195
citing authors

#	ARTICLE	IF	CITATIONS
1	Circulating CTRP9 Is Associated With Severity of Systemic Sclerosis-Associated Interstitial Lung Disease. <i>Arthritis Care and Research</i> , 2023, 75, 152-157.	3.4	7
2	Heterogeneity of primary and secondary peristalsis in systemic sclerosis: A new model of scleroderma esophagus. <i>Neurogastroenterology and Motility</i> , 2022, 34, e14284.	3.0	3
3	Lung Injury Induces Alveolar Type 2 Cell Hypertrophy and Polyploidy with Implications for Repair and Regeneration. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2022, 66, 564-576.	2.9	14
4	High-throughput identification of autoantibodies that target the human exoproteome. <i>Cell Reports Methods</i> , 2022, 2, 100172.	2.9	22
5	FDG PET vascular imaging in IgG4-RD: Potential and challenges. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 2934-2937.	2.1	2
6	Mast cell activation in the systemic sclerosis esophagus. <i>Journal of Scleroderma and Related Disorders</i> , 2021, 6, 77-86.	1.7	1
7	Predictive Significance of Serum Interferon-Inducible Protein Score for Response to Treatment in Systemic Sclerosis-Related Interstitial Lung Disease. <i>Arthritis and Rheumatology</i> , 2021, 73, 1005-1013.	5.6	21
8	Large-scale Characterization of Systemic Sclerosis Serum Protein Profile: Comparison to Peripheral Blood Cell Transcriptome and Correlations With Skin/Lung Fibrosis. <i>Arthritis and Rheumatology</i> , 2021, 73, 660-670.	5.6	10
9	Soluble Biomarkers for Prediction of Vascular and Gastrointestinal Disease Severity in Patients with Systemic Sclerosis. <i>Current Treatment Options in Rheumatology</i> , 2021, 7, 21-38.	1.4	0
10	A review and roadmap of the skin, lung and gut microbiota in systemic sclerosis. <i>Rheumatology</i> , 2021, 60, 5498-5508.	1.9	2
11	The Association of COVID-19 With Acute Kidney Injury Independent of Severity of Illness: A Multicenter Cohort Study. <i>American Journal of Kidney Diseases</i> , 2021, 77, 490-499.e1.	1.9	58
12	Clinical characteristics, visceral involvement, and mortality in at-risk or early diffuse systemic sclerosis: a longitudinal analysis of an observational prospective multicenter US cohort. <i>Arthritis Research and Therapy</i> , 2021, 23, 170.	3.5	30
13	Esophageal Dilation and Other Clinical Factors Associated With Pulmonary Function Decline in Patients With Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1830-1838.	2.0	4
14	Impaired Myocardial Flow Reserve on ⁸² Rubidium Positron Emission Tomography/Computed Tomography in Patients With Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2021, 48, 1574-1582.	2.0	2
15	Association Between Impaired Myocardial Flow Reserve on ⁸² Rubidium Positron Emission Tomography Imaging and Adverse Events in Patients With Autoimmune Rheumatic Disease. <i>Circulation: Cardiovascular Imaging</i> , 2021, 14, e012208.	2.6	7
16	Electronic health record alerts for acute kidney injury: multicenter, randomized clinical trial. <i>BMJ</i> , 2021, 372, m4786.	6.0	96
17	Computer vision applied to dual-energy computed tomography images for precise calcinosis cutis quantification in patients with systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2021, 23, 6.	3.5	17
18	Global skin gene expression analysis of early diffuse cutaneous systemic sclerosis shows a prominent innate and adaptive inflammatory profile. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 379-386.	0.9	97

#	ARTICLE	IF	CITATIONS
19	Lenabasum for Skin Disease in Patients With Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1237-1240.	5.6	8
20	Current and Potential New Targets in Systemic Sclerosis Therapy: a New Hope. <i>Current Rheumatology Reports</i> , 2020, 22, 42.	4.7	32
21	Calcinosis is associated with ischemic manifestations and increased disability in patients with systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2020, 50, 891-896.	3.4	26
22	High-throughput quantitative histology in systemic sclerosis skin disease using computer vision. <i>Arthritis Research and Therapy</i> , 2020, 22, 48.	3.5	7
23	Profibrotic Activation of Human Macrophages in Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1160-1169.	5.6	47
24	Performance Characteristics of Pulmonary Function Tests for the Detection of Interstitial Lung Disease in Adults With Early Diffuse Cutaneous Systemic Sclerosis. <i>Arthritis and Rheumatology</i> , 2020, 72, 1892-1896.	5.6	36
25	Regulator combinations identify systemic sclerosis patients with more severe disease. <i>JCI Insight</i> , 2020, 5, .	5.0	2
26	Molecular "omic" signatures in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, S173-S180.	0.6	1
27	Molecular "omic" signatures in systemic sclerosis. <i>European Journal of Rheumatology</i> , 2020, 7, 173-180.	0.6	6
28	Connective Tissue Disease-Associated Interstitial Lung Disease. <i>Clinics in Chest Medicine</i> , 2019, 40, 617-636.	2.1	10
29	Myeloablation followed by autologous stem cell transplantation normalises systemic sclerosis molecular signatures. <i>Annals of the Rheumatic Diseases</i> , 2019, 78, 1371-1378.	0.9	43
30	Towards a new classification of systemic sclerosis. <i>Nature Reviews Rheumatology</i> , 2019, 15, 456-457.	8.0	17
31	Complementary therapies for patients with systemic sclerosis. <i>Journal of Scleroderma and Related Disorders</i> , 2019, 4, 187-199.	1.7	2
32	Increased monocyte count as a cellular biomarker for poor outcomes in fibrotic diseases: a retrospective, multicentre cohort study. <i>Lancet Respiratory Medicine</i> , 2019, 7, 497-508.	10.7	168
33	Normal Values of Esophageal Distensibility and Distension-Induced Contractility Measured by Functional Luminal Imaging Probe Panometry. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 674-681.e1.	4.4	107
34	Mycophenolate Mofetil Treatment of Systemic Sclerosis Reduces Myeloid Cell Numbers and Attenuates the Inflammatory Gene Signature in Skin. <i>Journal of Investigative Dermatology</i> , 2018, 138, 1301-1310.	0.7	45
35	Transcriptional Profiling of Synovial Macrophages Using Minimally Invasive Ultrasound-Guided Synovial Biopsies in Rheumatoid Arthritis. <i>Arthritis and Rheumatology</i> , 2018, 70, 841-854.	5.6	44
36	Performance of Forced Vital Capacity and Lung Diffusion Cutpoints for Associated Radiographic Interstitial Lung Disease in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2018, 45, 1572-1576.	2.0	41

#	ARTICLE	IF	CITATIONS
37	The Scleroderma Patient-Centered Intervention Network Cohort: baseline clinical features and comparison with other large scleroderma cohorts. <i>Rheumatology</i> , 2018, 57, 1623-1631.	1.9	53
38	The novel adipokine C1q-TNF related protein 9 (CTRP9) is elevated in systemic sclerosis-associated interstitial lung disease. <i>Clinical and Experimental Rheumatology</i> , 2018, 36 Suppl 113, 184-185.	0.8	4
39	A novel multi-network approach reveals tissue-specific cellular modulators of fibrosis in systemic sclerosis. <i>Genome Medicine</i> , 2017, 9, 27.	8.2	92
40	Monocyte-derived alveolar macrophages drive lung fibrosis and persist in the lung over the life span. <i>Journal of Experimental Medicine</i> , 2017, 214, 2387-2404.	8.5	755
41	Controversies: molecular vs. clinical systemic sclerosis classification. <i>Journal of Scleroderma and Related Disorders</i> , 2016, 1, 277-285.	1.7	16
42	Loss of Peristaltic Reserve, Determined by Multiple Rapid Swallows, Is the Most Frequent Esophageal Motility Abnormality in Patients With Systemic Sclerosis. <i>Clinical Gastroenterology and Hepatology</i> , 2016, 14, 1502-1506.	4.4	78
43	Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial. <i>Lancet Respiratory Medicine</i> , 2016, 4, 708-719.	10.7	754
44	Tenascin-C drives persistence of organ fibrosis. <i>Nature Communications</i> , 2016, 7, 11703.	12.8	204
45	Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 344-349.	3.4	66
46	Comment on "Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study". <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, e11-e12.	3.4	1
47	Genetic susceptibility loci of idiopathic interstitial pneumonia do not represent risk for systemic sclerosis: a case control study in Caucasian patients. <i>Arthritis Research and Therapy</i> , 2016, 18, 20.	3.5	18
48	Esophageal dilatation and interstitial lung disease in systemic sclerosis: A cross-sectional study. <i>Seminars in Arthritis and Rheumatism</i> , 2016, 46, 109-114.	3.4	59
49	The relationship between skin symptoms and the scleroderma modification of the health assessment questionnaire, the modified Rodnan skin score, and skin pathology in patients with systemic sclerosis. <i>Rheumatology</i> , 2016, 55, 911-917.	1.9	29
50	Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity. <i>JCI Insight</i> , 2016, 1, e89073.	5.0	57
51	Molecular characterization of systemic sclerosis esophageal pathology identifies inflammatory and proliferative signatures. <i>Arthritis Research and Therapy</i> , 2015, 17, 194.	3.5	48
52	Serum Amyloid A Is a Marker for Pulmonary Involvement in Systemic Sclerosis. <i>PLoS ONE</i> , 2015, 10, e0110820.	2.5	34
53	Experimentally-Derived Fibroblast Gene Signatures Identify Molecular Pathways Associated with Distinct Subsets of Systemic Sclerosis Patients in Three Independent Cohorts. <i>PLoS ONE</i> , 2015, 10, e0114017.	2.5	62
54	Advances in the Evaluation and Management of Esophageal Disease of Systemic Sclerosis. <i>Current Rheumatology Reports</i> , 2015, 17, 475.	4.7	40

#	ARTICLE	IF	CITATIONS
55	Systems Level Analysis of Systemic Sclerosis Shows a Network of Immune and Profibrotic Pathways Connected with Genetic Polymorphisms. <i>PLoS Computational Biology</i> , 2015, 11, e1004005.	3.2	115
56	Survival in systemic sclerosisâ€“pulmonary arterial hypertension by serum autoantibody status in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) Registry. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 45, 309-314.	3.4	21
57	Longitudinal Evaluation of PROMIS-29 and FACIT-Dyspnea Short Forms in Systemic Sclerosis. <i>Journal of Rheumatology</i> , 2015, 42, 64-72.	2.0	44
58	Antinuclear antibody-negative systemic sclerosis. <i>Seminars in Arthritis and Rheumatism</i> , 2015, 44, 680-686.	3.4	60
59	A candidate gene study reveals association between a variant of the Peroxisome Proliferator-Activated Receptor Gamma (PPAR- γ) gene and systemic sclerosis. <i>Arthritis Research and Therapy</i> , 2015, 17, 128.	3.5	24
60	Survival and Predictors of Mortality in Systemic Sclerosisâ€“Associated Pulmonary Arterial Hypertension: Outcomes From the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Registry. <i>Arthritis Care and Research</i> , 2014, 66, 489-495.	3.4	132
61	Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. <i>Seminars in Arthritis and Rheumatism</i> , 2014, 44, 55-62.	3.4	69
62	Systemic sclerosis: beyond limited and diffuse subsets?. <i>Nature Reviews Rheumatology</i> , 2014, 10, 200-202.	8.0	31
63	ImmunoChIP Analysis Identifies Multiple Susceptibility Loci for Systemic Sclerosis. <i>American Journal of Human Genetics</i> , 2014, 94, 47-61.	6.2	182
64	Early Growth Response 3 (Egr-3) Is Induced by Transforming Growth Factor- β 2 and Regulates Fibrogenic Responses. <i>American Journal of Pathology</i> , 2013, 183, 1197-1208.	3.8	48
65	Molecular Signatures in Skin Associated with Clinical Improvement during Mycophenolate Treatment in Systemic Sclerosis. <i>Journal of Investigative Dermatology</i> , 2013, 133, 1979-1989.	0.7	150
66	Treatment of early diffuse systemic sclerosis skin disease. <i>Clinical and Experimental Rheumatology</i> , 2013, 31, 166-71.	0.8	30
67	The Pulmonary Fibrosis-Associated MUC5B Promoter Polymorphism Does Not Influence the Development of Interstitial Pneumonia in Systemic Sclerosis. <i>Chest</i> , 2012, 142, 1584-1588.	0.8	61
68	Text data extraction for a prospective, research-focused data mart: implementation and validation. <i>BMC Medical Informatics and Decision Making</i> , 2012, 12, 106.	3.0	13
69	Levels of adiponectin, a marker for PPAR-gamma activity, correlate with skin fibrosis in systemic sclerosis: potential utility as a biomarker?. <i>Arthritis Research and Therapy</i> , 2012, 14, R102.	3.5	81
70	Fibrosis in systemic sclerosis: common and unique pathobiology. <i>Fibrogenesis and Tissue Repair</i> , 2012, 5, S18.	3.4	31
71	Prevalence, prognosis, and factors associated with left ventricular diastolic dysfunction in systemic sclerosis. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S30-7.	0.8	49
72	Imatinib mesylate causes genome-wide transcriptional changes in systemic sclerosis fibroblasts in vitro. <i>Clinical and Experimental Rheumatology</i> , 2012, 30, S86-96.	0.8	10

#	ARTICLE	IF	CITATIONS
73	Validity of two new patient-reported outcome measures in systemic sclerosis: Patient-reported outcomes measurement information system 29-item health profile and functional assessment of chronic illness therapy-dyspnea short form. <i>Arthritis Care and Research</i> , 2011, 63, 1620-1628.	3.4	101
74	Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS): Baseline Characteristics and Description of Study Population. <i>Journal of Rheumatology</i> , 2011, 38, 2172-2179.	2.0	90
75	Identification of Novel Genetic Markers Associated with Clinical Phenotypes of Systemic Sclerosis through a Genome-Wide Association Strategy. <i>PLoS Genetics</i> , 2011, 7, e1002178.	3.5	201
76	Genome-wide association study of systemic sclerosis identifies CD247 as a new susceptibility locus. <i>Nature Genetics</i> , 2010, 42, 426-429.	21.4	351
77	Systemic sclerosis/scleroderma: a treatable multisystem disease. <i>American Family Physician</i> , 2008, 78, 961-8.	0.1	53
78	Obliterative vasculopathy in systemic sclerosis: endothelial precursor cells as novel targets for therapy. <i>Expert Review of Clinical Immunology</i> , 2007, 3, 11-15.	3.0	4
79	Novel paradigm for treating vasculopathy in systemic sclerosis: Vascular progenitor cells and statins. <i>Current Rheumatology Reports</i> , 2007, 9, 1-3.	4.7	2
80	A genomic meta-analysis of clinical variables and their association with intrinsic molecular subsets in systemic sclerosis. <i>Rheumatology</i> , 0, , .	1.9	5